Europe In-Vitro Diagnostics Market: 2030 Trends & Forecast

Name: Europe In-Vitro Diagnostics Market: 2030 Trends & Forecast
Creator: Next Move Strategy Consulting
Published: 2025-08-14T20:00:00-04:00
License: https://www.nextmsc.com/privacy-policy

About Report

Download Now

Europe In-Vitro Diagnostic Market By Product & Service (Reagents & Consumables, Instruments & Devices, and Software & Services), By Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, and Others), By Testing Site/Channel (Central & Reference Laboratories, Hospital & Physician Labs, Point-of-Care & Retail, and Others), By Application (Infectious Diseases, Oncology, Cardiovascular Health, and Others) – Opportunity Analysis and Industry Forecast, 2024–2030.

Download PDF

Speak to Our Analyst

Europe In-Vitro Diagnostics Market Overview

The Europe In-Vitro Diagnostics Market size was valued at USD 14.89 billion in 2023, and is predicted to reach USD 18.67 billion by 2030, at a CAGR of 2.9% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

IVD tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, these tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics. Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Growing Aging Population in Europe Drives Significant Market Growth

Europe's aging demographic profile amplifies the need for immunodiagnostic innovations, as age-related ailments become more prevalent. Technological advancements and the advent of sophisticated diagnostic techniques are revolutionizing the landscape, enhancing the accuracy and accessibility of diagnostic tests. This, coupled with supportive governmental policies aimed at enhancing healthcare infrastructure and accessibility, creates a favourable environment for in-vitro diagnostics market expansion in the region.

Adoption of Strategic Investments and Collaborations Boost the Market Growth

The strategic investments in research and development, alongside collaborative efforts within the industry, propel innovation and drive the development of cutting-edge diagnostic tools. Adopting personalized medicine principles and widespread use of point-of-care testing additionally stimulate the Europe in-vitro diagnostics market growth, heralding a significant change in healthcare provision throughout the region.

High Research, Development, and Regulatory Approval Costs Hinder Vitro Diagnostics Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the in-vitro diagnostics market growth in Europe. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Market Opportunity

Point-of-care testing (POCT) is poised to be a significant driver of growth in the Europe IVD market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Germany Dominates the Europe In-Vitro Diagnostics Market Share

The substantial healthcare expenditure is significant in propelling the growth of the in-vitro diagnostics market in this region. Germany allocates substantial resources towards improving healthcare infrastructure, enhancing medical facilities, and expanding access to healthcare services, including diagnostic testing.

Germany's health expenditure per capita stands at USD 8011, surpassing the OECD average of USD 4986. This accounts for 12.7% of the country's GDP, notably higher than the OECD average of 9.2%. This increased investment enables healthcare facilities to adopt innovative in-vitro diagnostics products and platforms offering more accurate, efficient, and timely diagnostic capabilities.

Finland to Witness Substantial Growth in the Market

The increasing incidence of chronic diseases is boosting the need for advanced diagnostic techniques, thereby propelling the growth of the Europe in-vitro diagnostics market trends. According to European Observatory on Health System and Policies, in 2021, the primary causes of mortality in Finland were circulatory diseases, specifically ischemic heart diseases and stroke, followed by cancer, Alzheimer’s and other dementias.

Collectively, these ailments constituted approximately three-quarters of all reported deaths in Finland. This rising incidence of chronic diseases and mortality is boosting the demand for advanced diagnostic techniques in Finland's healthcare landscape to detect and manage these conditions effectively, the in-vitro diagnostics market is positioned to play a pivotal role in improving patient outcomes and reducing the burden of chronic diseases in Finland.

Competitive Landscape

The promising players operating in the Europe in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Europe In-Vitro Diagnostics Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

By Country

The UK
Germany
France
Italy
Spain
Denmark
Netherlands
Finland
Sweden
Norway
Russia
Rest of Europe

KEY PLAYERS

Roche Holding AG
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.

Report Scope and Segmentation

Parameters	Details
Market Size Value in 2023	USD 14.89 billion
Revenue Forecast in 2030	USD 18.67 billion
Value Growth Rate	CAGR of 2.9% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Growing Aging Population in Europe Drives Significant Market Growth. Adoption of Strategic Investments and Collaboration Boosts the Market Growth.
Companies Profiled	10
Countries Covered	11
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

About the Author

Sikha Haritwal is an assistant manager with strong expertise in market research, data analysis, and cross-functional coordination. She plays a key role in leading complex research initiatives, strengthening analytical rigor, and enabling data-driven decision-making across teams. Known for her leadership mindset and structured problem-solving approach, she supports process improvement, enhances operational efficiency, and contributes to building scalable frameworks that drive long-term strategic outcomes and organizational effectiveness.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2023 - 2030, MILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 DRIVER 1
  2. 5.1.2 DRIVER 2
  3. 5.1.3 DRIVER 3
  4. 5.1.4 DRIVER 4
3. 5.2 CHALLENGES
4. 1. 5.2.1 CHALLENGE 1
  2. 5.2.2 CHALLENGE 2
  3. 5.2.3 CHALLENGE 3
  4. 5.2.4 CHALLENGE 4
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 OPPORTUNITY 1
  2. 5.3.2 OPPORTUNITY 2

1. 6.1 OVERVIEW
2. 6.2 REAGENTS
3. 1. 6.2.1 REAGENTS MARKET, BY COUNTRY
4. 6.3 INSTRUMENTS
5. 1. 6.3.1 INSTRUMENTS MARKET, BY COUNTRY
6. 6.4 SOFTWARE AND SERVICES
7. 1. 6.4.1 SOFTWARE AND SERVICES MARKET, BY COUNTRY

1. 7.1 OVERVIEW
2. 7.2 IMMUNODIAGNOSTICS
3. 1. 7.2.1 IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE
  2. 1. 7.2.1.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY COUNTRY
    2. 7.2.1.2 RAPID TESTS MARKET, BY COUNTRY
    3. 7.2.1.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY COUNTRY
    4. 7.2.1.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY COUNTRY
    5. 7.2.1.5 RADIOIMMUNOASSAY (RIA) MARKET, BY COUNTRY
    6. 7.2.1.6 WESTERN BLOT MARKET, BY COUNTRY
  3. 7.2.2 IMMUNODIAGNOSTICS MARKET, BY COUNTRY
4. 7.3 HEMATOLOGY
5. 1. 7.3.1 HEMATOLOGY MARKET, BY COUNTRY
6. 7.4 MOLECULAR DIAGNOSTICS
7. 1. 7.4.1 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE
  2. 1. 7.4.1.1 PCR MARKET, BY COUNTRY
    2. 7.4.1.2 INAAT MARKET, BY COUNTRY
    3. 7.4.1.3 HYBRIDIZATION MARKET, BY COUNTRY
    4. 7.4.1.4 DNA DIAGNOSTICS MARKET, BY COUNTRY
    5. 7.4.1.5 MICROARRAY MARKET, BY COUNTRY
    6. 7.4.1.6 OTHER MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
  3. 7.4.2 MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
8. 7.5 TISSUE DIAGNOSTICS
9. 1. 7.5.1 TISSUE DIAGNOSTICS MARKET, BY COUNTRY
10. 7.6 CLINICAL CHEMISTRY
11. 1. 7.6.1 CLINICAL CHEMISTRY MARKET, BY TECHNIQUE
  2. 1. 7.6.1.1 BASIC METABOLIC PANEL MARKET, BY COUNTRY
    2. 7.6.1.2 LIVER PANEL MARKET, BY COUNTRY
    3. 7.6.1.3 RENAL PROFILE MARKET, BY COUNTRY
    4. 7.6.1.4 LIPID PROFILE MARKET, BY COUNTRY
    5. 7.6.1.5 THYROID FUNCTION PANEL MARKET, BY COUNTRY
    6. 7.6.1.6 ELECTROLYTE PANEL MARKET, BY COUNTRY
    7. 7.6.1.7 SPECIALITY CHEMICALS MARKET, BY COUNTRY
  3. 7.6.2 CLINICAL CHEMISTRY MARKET, BY COUNTRY
12. 7.7 OTHER IVD TECHNIQUES
13. 1. 7.7.1 OTHER IVD TECHNIQUES MARKET, BY COUNTRY

1. 8.1 OVERVIEW
2. 8.2 INFECTIOUS DISEASES
3. 1. 8.2.1 INFECTIOUS DISEASES MARKET, BY COUNTRY
4. 8.3 CANCER
5. 1. 8.3.1 CANCER MARKET, BY COUNTRY
6. 8.4 CARDIAC DISEASES
7. 1. 8.4.1 CARDIAC DISEASES MARKET, BY COUNTRY
8. 8.5 IMMUNE SYSTEM DISORDERS
9. 1. 8.5.1 IMMUNE SYSTEM DISORDERS MARKET, BY COUNTRY
10. 8.6 NEPHROLOGICAL DISEASES
11. 1. 8.6.1 NEPHROLOGICAL DISEASES MARKET, BY COUNTRY
12. 8.7 GASTROINTESTINAL DISEASES
13. 1. 8.7.1 GASTROINTESTINAL DISEASES MARKET, BY COUNTRY
14. 8.8 OTHERS
15. 1. 8.8.1 OTHERS MARKET, BY COUNTRY

1. 9.1 OVERVIEW
2. 9.2 STAND ALONE LABORATORY
3. 1. 9.2.1 STAND ALONE LABORATORY MARKET, BY COUNTRY
4. 9.3 HOSPITALS
5. 1. 9.3.1 HOSPITALS MARKET, BY COUNTRY
6. 9.4 ACADEMICS AND MEDICAL SCHOOLS
7. 1. 9.4.1 ACADEMICS AND MEDICAL SCHOOLS MARKET, BY COUNTRY
8. 9.5 POINT OF CARE TESTING
9. 1. 9.5.1 POINT OF CARE TESTING MARKET, BY COUNTRY
10. 9.6 OTHER END USERS
11. 1. 9.6.1 OTHER END USERS MARKET, BY COUNTRY

1. 10.1 OVERVIEW
2. 10.2 GERMANY
3. 1. 10.2.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.2.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.2.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.2.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
4. 10.3 FRANCE
5. 1. 10.3.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.3.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.3.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.3.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
6. 10.4 ITALY
7. 1. 10.4.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.4.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.4.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.4.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
8. 10.5 SPAIN
9. 1. 10.5.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.5.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.5.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.5.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
10. 10.6 UNITED KINGDOM
11. 1. 10.6.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.6.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.6.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.6.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
12. 10.7 RUSSIA
13. 1. 10.7.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.7.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.7.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.7.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
14. 10.8 SWEDEN
15. 1. 10.8.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.8.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.8.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.8.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
16. 10.9 NORWAY
17. 1. 10.9.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.9.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.9.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.9.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
18. 10.10 DENMARK
19. 1. 10.10.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.10.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.10.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.10.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
20. 10.11 NETHERLANDS
21. 1. 10.11.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.11.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.11.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.11.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
22. 10.12 FINLAND
23. 1. 10.12.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.12.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.12.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.12.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER
24. 10.13 REST OF EUROPE
25. 1. 10.13.1 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TYPE
  2. 10.13.2 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.13.3 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.13.4 EUROPE IN-VITRO DIAGNOSTICS MARKET, BY END USER

1. 11.1 ROCHE HOLDING AG
2. 1. 11.1.1 COMPANY OVERVIEW
  2. 11.1.2 COMPANY SNAPSHOT
  3. 11.1.3 OPERATING BUSINESS SEGMENTS
  4. 11.1.4 PRODUCT PORTFOLIO
  5. 11.1.5 BUSINESS PERFORMANCE
  6. 11.1.6 BUSINESS SEGMENTS
  7. 11.1.7 GEOGRAPHIC SEGMENTS
  8. 11.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.1.9 PRIMARY MARKET COMPETITORS
3. 11.2 ABBOTT LABORATORIES
4. 1. 11.2.1 COMPANY OVERVIEW
  2. 11.2.2 COMPANY SNAPSHOT
  3. 11.2.3 OPERATING BUSINESS SEGMENTS
  4. 11.2.4 PRODUCT PORTFOLIO
  5. 11.2.5 BUSINESS PERFORMANCE
  6. 11.2.6 BUSINESS SEGMENTS
  7. 11.2.7 GEOGRAPHIC SEGMENTS
  8. 11.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.2.9 PRIMARY MARKET COMPETITORS
5. 11.3 THERMO FISHER SCIENTIFIC INC.
6. 1. 11.3.1 COMPANY OVERVIEW
  2. 11.3.2 COMPANY SNAPSHOT
  3. 11.3.3 OPERATING BUSINESS SEGMENTS
  4. 11.3.4 PRODUCT PORTFOLIO
  5. 11.3.5 BUSINESS PERFORMANCE
  6. 11.3.6 BUSINESS SEGMENTS
  7. 11.3.7 GEOGRAPHIC SEGMENTS
  8. 11.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.3.9 PRIMARY MARKET COMPETITORS
7. 11.4 DANAHER CORPORATION
8. 1. 11.4.1 COMPANY OVERVIEW
  2. 11.4.2 COMPANY SNAPSHOT
  3. 11.4.3 OPERATING BUSINESS SEGMENTS
  4. 11.4.4 PRODUCT PORTFOLIO
  5. 11.4.5 BUSINESS PERFORMANCE
  6. 11.4.6 BUSINESS SEGMENTS
  7. 11.4.7 GEOGRAPHIC SEGMENTS
  8. 11.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.4.9 PRIMARY MARKET COMPETITORS
9. 11.5 BECTON, DICKINSON AND COMPANY
10. 1. 11.5.1 COMPANY OVERVIEW
  2. 11.5.2 COMPANY SNAPSHOT
  3. 11.5.3 OPERATING BUSINESS SEGMENTS
  4. 11.5.4 PRODUCT PORTFOLIO
  5. 11.5.5 BUSINESS PERFORMANCE
  6. 11.5.6 BUSINESS SEGMENTS
  7. 11.5.7 GEOGRAPHIC SEGMENTS
  8. 11.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.5.9 PRIMARY MARKET COMPETITORS
11. 11.6 SIEMENS HEALTHINEERS AG
12. 1. 11.6.1 COMPANY OVERVIEW
  2. 11.6.2 COMPANY SNAPSHOT
  3. 11.6.3 OPERATING BUSINESS SEGMENTS
  4. 11.6.4 PRODUCT PORTFOLIO
  5. 11.6.5 BUSINESS PERFORMANCE
  6. 11.6.6 BUSINESS SEGMENTS
  7. 11.6.7 GEOGRAPHIC SEGMENTS
  8. 11.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.6.9 PRIMARY MARKET COMPETITORS
13. 11.7 BIOMÉRIEUX SA
14. 1. 11.7.1 COMPANY OVERVIEW
  2. 11.7.2 COMPANY SNAPSHOT
  3. 11.7.3 OPERATING BUSINESS SEGMENTS
  4. 11.7.4 PRODUCT PORTFOLIO
  5. 11.7.5 BUSINESS PERFORMANCE
  6. 11.7.6 BUSINESS SEGMENTS
  7. 11.7.7 GEOGRAPHIC SEGMENTS
  8. 11.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.7.9 PRIMARY MARKET COMPETITORS
15. 11.8 SYSMEX CORPORATION
16. 1. 11.8.1 COMPANY OVERVIEW
  2. 11.8.2 COMPANY SNAPSHOT
  3. 11.8.3 OPERATING BUSINESS SEGMENTS
  4. 11.8.4 PRODUCT PORTFOLIO
  5. 11.8.5 BUSINESS PERFORMANCE
  6. 11.8.6 BUSINESS SEGMENTS
  7. 11.8.7 GEOGRAPHIC SEGMENTS
  8. 11.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.8.9 PRIMARY MARKET COMPETITORS
17. 11.9 QIAGEN N.V.
18. 1. 11.9.1 COMPANY OVERVIEW
  2. 11.9.2 COMPANY SNAPSHOT
  3. 11.9.3 OPERATING BUSINESS SEGMENTS
  4. 11.9.4 PRODUCT PORTFOLIO
  5. 11.9.5 BUSINESS PERFORMANCE
  6. 11.9.6 BUSINESS SEGMENTS
  7. 11.9.7 GEOGRAPHIC SEGMENTS
  8. 11.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.9.9 PRIMARY MARKET COMPETITORS
19. 11.10 BIO-RAD LABORATORIES, INC.
20. 1. 11.10.1 COMPANY OVERVIEW
  2. 11.10.2 COMPANY SNAPSHOT
  3. 11.10.3 OPERATING BUSINESS SEGMENTS
  4. 11.10.4 PRODUCT PORTFOLIO
  5. 11.10.5 BUSINESS PERFORMANCE
  6. 11.10.6 BUSINESS SEGMENTS
  7. 11.10.7 GEOGRAPHIC SEGMENTS
  8. 11.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.10.9 PRIMARY MARKET COMPETITORS

TABLE 1. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 2. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 3. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 5. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 6. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 7. RAPID TESTS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 8. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 9. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 10. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 11. WESTERN BLOT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 12. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 13. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 14. PCR, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 15. INAAT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 16. HYBRIDIZATION, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 17. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 18. MICROARRAY, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 19. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 20. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 21. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 22. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 23. LIVER PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 24. RENAL PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 25. LIPID PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 26. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 27. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 28. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)
TABLE 29. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 31. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 33. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 34. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 38. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 39. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 41. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 43. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 44. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 45. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
TABLE 46. GERMANY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 47. GERMANY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 48. GERMANY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 49. GERMANY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 50. FRANCE EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 51. FRANCE EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 52. FRANCE EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 53. FRANCE EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 54. ITALY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 55. ITALY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 56. ITALY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 57. ITALY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 58. SPAIN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 59. SPAIN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 60. SPAIN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 61. SPAIN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 62. UNITED KINGDOM EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 63. UNITED KINGDOM EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 64. UNITED KINGDOM EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 65. UNITED KINGDOM EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 66. RUSSIA EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 67. RUSSIA EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 68. RUSSIA EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 69. RUSSIA EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 70. SWEDEN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 71. SWEDEN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 72. SWEDEN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 73. SWEDEN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 74. NORWAY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 75. NORWAY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 76. NORWAY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 77. NORWAY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 78. DENMARK EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 79. DENMARK EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 80. DENMARK EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 81. DENMARK EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 82. NETHERLANDS EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 83. NETHERLANDS EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 84. NETHERLANDS EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 85. NETHERLANDS EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 86. FINLAND EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 87. FINLAND EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 88. FINLAND EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 89. FINLAND EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 90. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
TABLE 91. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
TABLE 92. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
TABLE 93. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
TABLE 94. ROCHE HOLDING AG: COMPANY SNAPSHOT
TABLE 95. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS
TABLE 96. ROCHE HOLDING AG: PRODUCT PORTFOLIO
TABLE 97. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 98. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 99. ROCHE HOLDING AG: KEY STRATERGY
TABLE 100. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 101. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 102. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 103. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 104. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 105. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 106. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 107. THERMO FISHER SCIENTIFIC INC.: OPERATING BUSINESS SEGMENTS
TABLE 108. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 109. THERMO FISHER SCIENTIFIC INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 110. THERMO FISHER SCIENTIFIC INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 111. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGY
TABLE 112. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 113. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 114. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 115. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 116. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 117. DANAHER CORPORATION: KEY STRATERGY
TABLE 118. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 119. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 120. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 121. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 122. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 123. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 124. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 125. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 126. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 127. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 128. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 129. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 130. BIOMéRIEUX SA: COMPANY SNAPSHOT
TABLE 131. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS
TABLE 132. BIOMéRIEUX SA: PRODUCT PORTFOLIO
TABLE 133. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 134. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 135. BIOMéRIEUX SA: KEY STRATERGY
TABLE 136. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 137. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 138. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 139. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 140. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 141. SYSMEX CORPORATION: KEY STRATERGY
TABLE 142. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 143. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 144. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 145. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 146. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 147. QIAGEN N.V.: KEY STRATERGY
TABLE 148. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 149. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS
TABLE 150. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 151. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)
TABLE 152. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)
TABLE 153. BIO-RAD LABORATORIES, INC.: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)
FIGURE 7. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 8. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 10. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)
FIGURE 11. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 12. RAPID TESTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 13. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 14. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 15. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 16. WESTERN BLOT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 17. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 18. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 19. PCR, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 20. INAAT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 21. HYBRIDIZATION, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 22. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 23. MICROARRAY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 24. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 26. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 27. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 28. LIVER PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 29. RENAL PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 30. LIPID PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 31. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 32. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 33. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 34. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 36. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)
FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 38. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 39. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 43. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 44. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)
FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 46. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 49. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)
FIGURE 50. EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY REGION 2023-2030, (MILLION USD)
FIGURE 51. GERMANY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 52. GERMANY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 53. GERMANY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 54. GERMANY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 55. FRANCE EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 56. FRANCE EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 57. FRANCE EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 58. FRANCE EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 59. ITALY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 60. ITALY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 61. ITALY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 62. ITALY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 63. SPAIN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 64. SPAIN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 65. SPAIN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 66. SPAIN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 67. UNITED KINGDOM EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 68. UNITED KINGDOM EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 69. UNITED KINGDOM EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 70. UNITED KINGDOM EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 71. RUSSIA EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 72. RUSSIA EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 73. RUSSIA EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 74. RUSSIA EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 75. SWEDEN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 76. SWEDEN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 77. SWEDEN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 78. SWEDEN EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 79. NORWAY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 80. NORWAY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 81. NORWAY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 82. NORWAY EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 83. DENMARK EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 84. DENMARK EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 85. DENMARK EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 86. DENMARK EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 87. NETHERLANDS EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 88. NETHERLANDS EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 89. NETHERLANDS EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 90. NETHERLANDS EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 91. FINLAND EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 92. FINLAND EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 93. FINLAND EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 94. FINLAND EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 95. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)
FIGURE 96. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)
FIGURE 97. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)
FIGURE 98. REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)
FIGURE 99. ROCHE HOLDING AG: NET SALES, (2021-2023)
FIGURE 100. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS
FIGURE 101. ABBOTT LABORATORIES: NET SALES, (2021-2023)
FIGURE 102. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 103. THERMO FISHER SCIENTIFIC INC.: NET SALES, (2021-2023)
FIGURE 104. THERMO FISHER SCIENTIFIC INC.: PRIMARY MARKET COMPETITORS
FIGURE 105. DANAHER CORPORATION: NET SALES, (2021-2023)
FIGURE 106. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 107. BECTON, DICKINSON AND COMPANY: NET SALES, (2021-2023)
FIGURE 108. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 109. SIEMENS HEALTHINEERS AG: NET SALES, (2021-2023)
FIGURE 110. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 111. BIOMéRIEUX SA: NET SALES, (2021-2023)
FIGURE 112. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS
FIGURE 113. SYSMEX CORPORATION: NET SALES, (2021-2023)
FIGURE 114. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 115. QIAGEN N.V.: NET SALES, (2021-2023)
FIGURE 116. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 117. BIO-RAD LABORATORIES, INC.: NET SALES, (2021-2023)
FIGURE 118. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Frequently Asked Questions

The Europe in-vitro diagnostics market revenue was valued at USD 14.89 billion in 2023 and is projected to grow at a size of CAGR of 2.9%, reaching a valuation of USD 18.67 billion by 2030.

The key market players in the Europe IVD industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Germany holds the largest share of the Europe in-vitro diagnostics market, owing to the rise in substantial healthcare expenditure in the region.

High costs associated with research, development, and regulatory approval are significant factors restraining in-vitro diagnostics market growth in the region.

Introduction of Point-of-Care Testing (POCT) solutions creates opportunities for the in-vitro diagnostics market in Europe, in the coming future.

Purchase Options Flash
sale

Multi User

$3,917 $5595

Single User

$3,217 $4595

Enterprise

$5,317 $7595

Datapack

$1,817 $2595

Download Sample

Inquire Before Buying